ArticleAnnals of intensive care2026
Comparison between regional citrate anticoagulation and systemic heparin anticoagulation in patients undergoing continuous renal replacement therapy and venoarterial extracorporeal membrane oxygenation: A retrospective multicentric study.
Article in Annals of intensive care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Regional citrate anticoagulation for renal replacement therapy during venovenous ECMO: A randomized crossover pilot study.Annals of intensive care · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Regional citrate anticoagulation (RCA) is the recommended first-line strategy for continuous renal replacement therapy (CRRT) circuits. Acute kidney injury is common in patients undergoing venoarterial extracorporeal membrane oxygenation (VA-ECMO), and CRRT is frequently required. However, the use of RCA in this setting remains debated due to concerns about metabolic complications and limited evidence. This study aimed to compare the efficacy and safety of RCA versus unfractionated heparin (UFH) anticoagulation in this high-risk population. Materials and methods: In this retrospective multicentric study, we included adult patients receiving simultaneous VA-ECMO and CRRT between January 2019 and December 2021 in four French intensive care units. The primary outcome was CRRT filter thrombosis, defined as unplanned circuit cessation due to clotting. Filter lifespan, defined as the time from CRRT initiation to cessation for any reason, was recorded as a secondary outcome. Additional secondary outcomes included bleeding events, transfusion requirements, coagulation parameters, and metabolic complications. Association of CRRT filter thrombosis with anticoagulation modality was assessed using a Fine-Gray regression model accounting for competing events, and adjusted for coagulation parameters and CRRT site. Missing data were handled using multiple imputation. Results: Among the 253 patients included (77.9% male, median age 61 years), 599 CRRT sessions were analyzed (RCA: 106; UFH: 493). Median filter lifespan did not differ significantly between groups (RCA: 47 [IQR 21-90] vs UFH: 44 [IQR 20-72] hours, p = 0.144). The estimated cumulative incidence of filter thrombosis at 72 h was 17.0% (95% CI, 10.5-24.8%) in the RCA group versus 26.6% (95% CI, 22.8-30.5%) in the UFH group; p = 0.033. RCA was associated with a significantly lower risk of filter thrombosis compared to UFH (aHR = 0.35 (95% CI, 0.21-0.59; p < 0.001)), after adjustment for coagulation parameters and CRRT site. RCA was not associated with decreased bleeding events (33.3% vs 37.6%, p = 0.417) and did not increase the incidence of severe metabolic complications. Conclusion: In patients receiving VA-ECMO and CRRT, RCA was safe and effective. RCA was associated with a significantly lower risk of filter thrombosis, despite similar median filter lifespan, without increasing bleeding or severe metabolic complications. These findings support the use of RCA as a promising anticoagulation strategy in this high-risk population. Specialty: Critical Care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.